Free Trial

ClearPoint Neuro (CLPT) Competitors

$7.07
+0.02 (+0.28%)
(As of 07/19/2024 ET)

CLPT vs. PDEX, STIM, TTOO, APYX, DRIO, CATX, ATRI, KIDS, EMBC, and SIBN

Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Pro-Dex (PDEX), Neuronetics (STIM), T2 Biosystems (TTOO), Apyx Medical (APYX), DarioHealth (DRIO), Perspective Therapeutics (CATX), Atrion (ATRI), OrthoPediatrics (KIDS), Embecta (EMBC), and SI-BONE (SIBN). These companies are all part of the "surgical & medical instruments" industry.

ClearPoint Neuro vs.

ClearPoint Neuro (NASDAQ:CLPT) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.

In the previous week, ClearPoint Neuro had 2 more articles in the media than Pro-Dex. MarketBeat recorded 2 mentions for ClearPoint Neuro and 0 mentions for Pro-Dex. ClearPoint Neuro's average media sentiment score of 0.50 beat Pro-Dex's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company Overall Sentiment
ClearPoint Neuro Positive
Pro-Dex Neutral

Pro-Dex received 128 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 60.91% of users gave Pro-Dex an outperform vote.

CompanyUnderperformOutperform
ClearPoint NeuroOutperform Votes
20
86.96%
Underperform Votes
3
13.04%
Pro-DexOutperform Votes
148
60.91%
Underperform Votes
95
39.09%

ClearPoint Neuro presently has a consensus price target of $12.00, suggesting a potential upside of 69.73%. Given ClearPoint Neuro's higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Pro-Dex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ClearPoint Neuro
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pro-Dex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by insiders. Comparatively, 42.6% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ClearPoint Neuro has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Pro-Dex has a net margin of 4.13% compared to ClearPoint Neuro's net margin of -78.84%. Pro-Dex's return on equity of 6.50% beat ClearPoint Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
ClearPoint Neuro-78.84% -76.92% -43.94%
Pro-Dex 4.13%6.50%4.01%

Pro-Dex has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ClearPoint Neuro$23.95M8.09-$22.09M-$0.84-8.42
Pro-Dex$46.09M1.45$7.07M$0.5833.79

Summary

Pro-Dex beats ClearPoint Neuro on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLPT vs. The Competition

MetricClearPoint NeuroSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$193.86M$3.87B$5.30B$8.23B
Dividend YieldN/A1.71%2.74%3.95%
P/E Ratio-8.4214.72155.0818.12
Price / Sales8.0968.092,148.7476.08
Price / CashN/A49.0836.1033.93
Price / Book8.224.274.864.42
Net Income-$22.09M$3.48M$111.86M$216.15M
7 Day Performance-5.98%-0.60%-0.66%-0.11%
1 Month Performance27.62%2.22%7.55%5.61%
1 Year Performance4.90%-17.09%4.33%1.32%

ClearPoint Neuro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PDEX
Pro-Dex
0 of 5 stars
0.00 / 5 stars
$18.51
+4.2%
N/A+4.4%$60.76M$46.09M31.91145Positive News
High Trading Volume
STIM
Neuronetics
2.7802 of 5 stars
2.78 / 5 stars
$1.89
+1.1%
$8.00
+323.3%
-6.6%$56.10M$71.35M-1.97203News Coverage
TTOO
T2 Biosystems
0.177 of 5 stars
0.18 / 5 stars
$5.60
+2.0%
$3.00
-46.4%
-49.4%$48.27M$7.19M0.00113News Coverage
APYX
Apyx Medical
3.7618 of 5 stars
3.76 / 5 stars
$1.37
-0.7%
$4.75
+246.7%
-77.0%$47.46M$52.35M-2.08252Positive News
DRIO
DarioHealth
0.8787 of 5 stars
0.88 / 5 stars
$1.45
+1.4%
$4.05
+179.3%
-70.9%$42.79M$20.35M-0.86276Positive News
Gap Down
CATX
Perspective Therapeutics
1.9196 of 5 stars
1.92 / 5 stars
$12.34
-4.4%
$19.00
+54.0%
N/A$803.81M$1.43M0.00116Positive News
ATRI
Atrion
3.31 of 5 stars
3.31 / 5 stars
$456.06
+0.1%
N/A-18.8%$801.85M$176.67M42.86720Analyst Forecast
News Coverage
Positive News
KIDS
OrthoPediatrics
3.4854 of 5 stars
3.49 / 5 stars
$32.88
+0.4%
$45.50
+38.4%
-25.8%$780.40M$148.73M-34.25247Analyst Forecast
EMBC
Embecta
0.9344 of 5 stars
0.93 / 5 stars
$12.84
-2.5%
$12.00
-6.5%
-33.4%$759.52M$1.12B10.612,200News Coverage
Gap Down
SIBN
SI-BONE
3.6541 of 5 stars
3.65 / 5 stars
$15.58
+1.7%
$25.67
+64.7%
-33.7%$631.26M$138.89M-14.29344

Related Companies and Tools

This page (NASDAQ:CLPT) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners